1. Home
  2. BODI vs RLYB Comparison

BODI vs RLYB Comparison

Compare BODI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Beachbody Company Inc.

BODI

The Beachbody Company Inc.

HOLD

Current Price

$10.45

Market Cap

82.8M

Sector

Industrials

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$14.29

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BODI
RLYB
Founded
1998
2018
Country
United States
United States
Employees
270
14
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.8M
75.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BODI
RLYB
Price
$10.45
$14.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
84.7K
293.5K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$20.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$3.38
$0.27
52 Week High
$16.87
$15.31

Technical Indicators

Market Signals
Indicator
BODI
RLYB
Relative Strength Index (RSI) 37.31 79.23
Support Level $9.55 $13.61
Resistance Level $10.92 $15.31
Average True Range (ATR) 1.48 0.70
MACD -0.56 0.03
Stochastic Oscillator 6.73 85.48

Price Performance

Historical Comparison
BODI
RLYB

About BODI The Beachbody Company Inc.

The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: